Treatment strategies for inclusion body myositis

Bibliography

• Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000;55(9):1385-7
   PubMed Web of Science ®Google Scholar
• Needham M, Corbett A, Day T, et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008;15(12):1350-3
   Google Scholar
• Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011;134(Pt 11):3176-84
   Google Scholar
• Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011;134(Pt 11):3167-75
   PubMedGoogle Scholar
• Rose MR. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013;23(12):1044-55
   Google Scholar
• Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 2014;83(5):426-33
   PubMed Web of Science ®Google Scholar
• Brady S, Squier W, Sewry C, et al. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open 2014;4(4):e004552
   PubMed Web of Science ®Google Scholar
• Schmidt J, Rakocevic G, Raju R, Dalakas MC. Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain 2004;127(Pt 5):1182-90
   Google Scholar
• van der Pas J, Hengstman GJ, ter Laak HJ, et al. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004;75(1):136-9
   PubMed Web of Science ®Google Scholar
• Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005;26(7):373-80
   Google Scholar
• Askanas V, Engel WK, Nogalska A. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J Neuropathol Exp Neurol 2012;71(8):680-93
   Google Scholar
• Schmidt J, Barthel K, Wrede A, et al. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008;131(Pt 5):1228-40
   Google Scholar
• Schmidt J, Barthel K, Zschuntzsch J, et al. Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1beta-induced accumulation of beta-amyloid and cell death. Brain 2012;135(Pt 4):1102-14
   Google Scholar
• Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998;21(1):115-17
   PubMed Web of Science ®Google Scholar
• Badrising UA, Schreuder GM, Giphart MJ, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004;63(12):2396-8
   Google Scholar
• Mastaglia FL, Needham M, Scott A, et al. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Disord 2009;19(11):763-5
   PubMed Web of Science ®Google Scholar
• Mastaglia FL, Rojana-udomsart A, James I, et al. Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. Neuromuscul Disord 2013;23(12):969-74
   Google Scholar
• Amemiya K, Granger RP, Dalakas MC. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 2000;123(Pt 10):2030-9
   PubMedGoogle Scholar
• Muntzing K, Lindberg C, Moslemi AR, Oldfors A. Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand J Immunol 2003;58(2):195-200
   Google Scholar
• De Bleecker JL, De Paepe B, Vanwalleghem IE, Schroder JM. Differential expression of chemokines in inflammatory myopathies. Neurology 2002;58(12):1779-85
   PubMed Web of Science ®Google Scholar
• Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003;28(6):659-82
   PubMed Web of Science ®Google Scholar
• Raju R, Vasconcelos O, Granger R, Dalakas MC. Expression of IFN-gamma-inducible chemokines in inclusion body myositis. J Neuroimmunol 2003;141(1-2):125-31
   Google Scholar
• Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 2000;97(16):9209-14
   Web of Science ®Google Scholar
• Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 1999;155(2):453-60
   PubMed Web of Science ®Google Scholar
• Wiendl H, Mitsdoerffer M, Schneider D, et al. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003;126(Pt 5):1026-35
   Google Scholar
• Wiendl H, Mitsdoerffer M, Schneider D, et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J 2003;17(13):1892-4
   PubMedGoogle Scholar
• Waschbisch A, Schwab N, Ruck T, et al. FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol 2010;225(1-2):137-42
   Google Scholar
• Allenbach Y, Chaara W, Rosenzwajg M, et al. Th1 response and systemic treg deficiency in inclusion body myositis. PLoS One 2014;9(3):e88788
   Google Scholar
• Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 2011;6(5):e20266
   Google Scholar
• Bradshaw EM, Orihuela A, McArdel SL, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007;178(1):547-56
   PubMed Web of Science ®Google Scholar
• Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005;65(11):1782-7
   Google Scholar
• Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5’-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73(3):408-18
   PubMed Web of Science ®Google Scholar
• Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 5’-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013;73(3):397-407
   PubMed Web of Science ®Google Scholar
• Fratta P, Engel WK, McFerrin J, et al. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am J Pathol 2005;167(2):517-26
   PubMed Web of Science ®Google Scholar
• Lunemann JD, Schmidt J, Schmid D, et al. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 2007;61(5):476-83
   PubMed Web of Science ®Google Scholar
• Wojcik S, Engel WK, McFerrin J, et al. AbetaPP-overexpression and proteasome inhibition increase alphaB-crystallin in cultured human muscle: relevance to inclusion-body myositis. Neuromuscul Disord 2006;16(12):839-44
   Google Scholar
• Vattemi G, Nogalska A, King Engel W, et al. Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Acta Neuropathol 2009;117(5):569-74
   Google Scholar
• Sarkozi E, Askanas V, Johnson SA, et al. beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 1993;4(6):815-18
   Google Scholar
• Vattemi G, Engel WK, McFerrin J, et al. Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet 2001;358(9297):1962-4
   Google Scholar
• Morosetti R, Mirabella M, Gliubizzi C, et al. MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. Proc Natl Acad Sci USA 2006;103(45):16995-7000
   PubMed Web of Science ®Google Scholar
• Morosetti R, Broccolini A, Sancricca C, et al. Increased aging in primary muscle cultures of sporadic inclusion-body myositis. Neurobiol Aging 2010;31(7):1205-14
   PubMed Web of Science ®Google Scholar
• Morosetti R, Gliubizzi C, Sancricca C, et al. TWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesis. Am J Pathol 2012;180(4):1603-13
   Google Scholar
• Keller CW, Schmitz M, Munz C, et al. TNF-alpha upregulates macroautophagic processing of APP/beta-amyloid in a human rhabdomyosarcoma cell line. J Neurol Sci 2013;325(1-2):103-7
   Google Scholar
• Keller CW, Fokken C, Turville SG, et al. TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. J Biol Chem 2011;286(5):3970-80
   Google Scholar
• Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 2008;64(1):15-24
   Google Scholar
• Muth IE, Barthel K, Bahr M, et al. Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid. J Neurol Neurosurg Psychiatry 2009;80(12):1344-9
   Google Scholar
• Vattemi G, Engel WK, McFerrin J, Askanas V. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol 2004;164(1):1-7
   PubMed Web of Science ®Google Scholar
• Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005;52(6):1824-35
   PubMed Web of Science ®Google Scholar
• Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995;45(7):1302-4
   PubMed Web of Science ®Google Scholar
• Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore) 1993;72(4):225-35
   PubMed Web of Science ®Google Scholar
• Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185(2):119-22
   Google Scholar
• Quartuccio L, De Marchi G, Scott CA, et al. Treatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features. Clin Exp Rheumatol 2007;25(2):246-51
   Google Scholar
• Badrising UA, Maat-Schieman ML, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002;51(3):369-72
   PubMed Web of Science ®Google Scholar
• Kelly JJ Jr, Madoc-Jones H, Adelman LS, et al. Total body irradiation not effective in inclusion body myositis. Neurology 1986;36(9):1264-6
   Google Scholar
• Dau PC. Leukocytapheresis in inclusion body myositis. J Clin Apher 1987;3(3):167-70
   Google Scholar
• Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004;63(4):718-20
   Google Scholar
• Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001;57(9):1566-70
   Google Scholar
• Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006;66(2 Suppl 1):S123-4
   PubMed Web of Science ®Google Scholar
• Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003;61(2):260-2
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009;132(Pt 6):1536-44
   PubMed Web of Science ®Google Scholar
• Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43(5):876-9
   PubMed Web of Science ®Google Scholar
• Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247(1):22-8
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56(3):323-7
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48(3):712-16
   PubMed Web of Science ®Google Scholar
• Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002;58(2):326
   PubMed Web of Science ®Google Scholar
• Pars K, Garde N, Skripuletz T, et al. Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. Muscle Nerve 2013;48(5):838-9
   PubMed Web of Science ®Google Scholar
• Breithaupt M, Schmidt J. Update on treatment of inclusion body myositis. Curr Rheumatol Rep 2013;15(5):329
   PubMed Web of Science ®Google Scholar
• Sanei-Moghaddam A, Kumar S, Jani P, Brierley C. Cricopharyngeal myotomy for cricopharyngeus stricture in an inclusion body myositis patient with hiatus hernia: a learning experience. BMJ Case Rep 2013;2013
   Google Scholar
• Liu LW, Tarnopolsky M, Armstrong D. Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol 2004;18(6):397-9
   Google Scholar
• Murata KY, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with Dysphagia. Clin Med Insights Case Rep 2013;6:1-7
   PubMedGoogle Scholar
• Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil 2008;87(11):883-9
   PubMed Web of Science ®Google Scholar
• Zschuntzsch J, Voss J, Creus K, et al. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and beta-amyloid in the muscle. Arthritis Rheum 2012;64(12):4094-103
   Google Scholar
• Rutkove SB, Parker RA, Nardin RA, et al. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002;58(7):1081-7
   PubMed Web of Science ®Google Scholar
• Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6(12):1399-402
   PubMed Web of Science ®Google Scholar
• Parihar A, Parihar MS, Zenebe WJ, Ghafourifar P. Statins lower calcium-induced oxidative stress in isolated mitochondria. Hum Exp Toxicol 2012;31(4):355-63
   Google Scholar
• Sancricca C, Mora M, Ricci E, et al. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci 2011;32(5):841-7
   Google Scholar
• Carstens PO, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol 2014;175(3):349-58
   PubMed Web of Science ®Google Scholar
• Touzot M, Soulillou JP, Dantal J. Mechanistic target of rapamycin inhibitors in solid organ transplantation: from benchside to clinical use. Curr Opin Organ Transplant 2012;17(6):626-33
   Google Scholar
• Prevel N, Allenbach Y, Klatzmann D, et al. Beneficial role of rapamycin in experimental autoimmune myositis. PLoS One 2013;8(11):e74450
   Google Scholar
• Ching JK, Elizabeth SV, Ju JS, et al. mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy. Hum Mol Genet 2013;22(6):1167-79
   PubMed Web of Science ®Google Scholar
• Graczyk PP. JNK inhibitors as anti-inflammatory and neuroprotective agents. Future Med Chem 2013;5(5):539-51
   PubMed Web of Science ®Google Scholar
• Kieran D, Kalmar B, Dick JR, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10(4):402-5
   PubMed Web of Science ®Google Scholar
• Vitecek J, Lojek A, Valacchi G, Kubala L. Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges. Mediators Inflamm 2012;2012:318087
   PubMedGoogle Scholar
• Zong M, Dorph C, Dastmalchi M, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis 2014;73(5):913-20
   PubMed Web of Science ®Google Scholar
• Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci 2013;334(1-2):123-5
   PubMed Web of Science ®Google Scholar
• Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 2011;50(7):1344-6
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65(2):314-24
   PubMed Web of Science ®Google Scholar
• Tournadre A, Lenief V, Miossec P. Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum 2010;62(7):2144-51
   Google Scholar
• Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis-a case-based review. Clin Rheumatol 2014. [ Epub ahead of print]
   Google Scholar
• Butini S, Brogi S, Novellino E, et al. The structural evolution of beta-secretase inhibitors: a focus on the development of small-molecule inhibitors. Curr Top Med Chem 2013;13(15):1787-807
   Google Scholar
• Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature 2003;423(6938):435-9
   PubMed Web of Science ®Google Scholar
• Terracciano C, Nogalska A, Engel WK, Askanas V. In AbetaPP-overexpressing cultured human muscle fibers, proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem 2010;112(2):389-96
   Google Scholar
• Kitazawa M, Vasilevko V, Cribbs DH, LaFerla FM. Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model. J Neurosci 2009;29(19):6132-41
   Google Scholar
• Li J, Horak KM, Su H, et al. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. J Clin Invest 2011;121(9):3689-700
   PubMed Web of Science ®Google Scholar